Co-Diagnostics (NASDAQ:CODX – Get Free Report) and Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.
Institutional & Insider Ownership
15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Co-Diagnostics has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Co-Diagnostics | 1 | 1 | 1 | 1 | 2.50 |
| Halozyme Therapeutics | 1 | 3 | 9 | 0 | 2.62 |
Co-Diagnostics presently has a consensus price target of $67.50, suggesting a potential upside of 6,650.00%. Halozyme Therapeutics has a consensus price target of $91.20, suggesting a potential downside of 18.29%. Given Co-Diagnostics’ higher possible upside, research analysts clearly believe Co-Diagnostics is more favorable than Halozyme Therapeutics.
Earnings & Valuation
This table compares Co-Diagnostics and Halozyme Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Co-Diagnostics | $721,386.00 | 9.68 | -$46.90 million | ($10.32) | -0.10 |
| Halozyme Therapeutics | $1.40 billion | 9.07 | $316.89 million | $3.35 | 33.32 |
Halozyme Therapeutics has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Co-Diagnostics and Halozyme Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Co-Diagnostics | -6,531.77% | -210.99% | -174.97% |
| Halozyme Therapeutics | 24.86% | 260.98% | 23.91% |
Summary
Halozyme Therapeutics beats Co-Diagnostics on 11 of the 15 factors compared between the two stocks.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
